Seize the opportunity to engage with key decision-makers seeking partnerships and solutions to accelerate the development and commercialization of oligonucleotide, peptide, and mRNA therapeutics. As a sponsor at TIDES Europe, you'll position your brand at the forefront of innovation, gaining unparalleled...
Thank you very much for your long-term strong support given to CSBio. We will be participating TIDES EUROPE:Oligonucleotide &Peptide Therapeutics, we sincerely welcome you visit us at our booth during this event. TIDES EUROPE Time: 12 - 14 Nov 2024 Address:Hamburg Congress Center,Germany CSBio...
Ribocure Pharmaceuticals Moves Into GoCo Clinic - Putting North Europe in the Spotlight Within Oligonucleotide Therapeutics Jun 29,2022 Ribocure Pharmaceuticals, the first overseas R&D center of Ribo based in Sweden, announces it will move in and open a clinical trial unit at GoCo Clinic - where...
In this 12-month, multicenter, open-label, multiple-dose, dose-escalation, phase 1b/2 trial (PQ-110-001; ClinicalTrials.gov identifier NCT03140969), patients received sepofarsen (QR-110; ProQR Therapeutics) into the worse-seeing eye (treated eye) by intravitreal injection following standard pr...
Therefore, such therapeutics could be applicable to a wide range of monogenic inherited retinal dystrophies. Importantly, the process of modulating pre-mRNA splicing ensures that the impact of the RNA therapeutic is fully reversible, and that the maximum treatment effect can only be to restore ...
非常感谢您对我们公司长期以来的大力支持,值此“TIDES EUROPE:Oligonucleotide &Peptide Therapeutics”到来之际,我们在此真诚的期盼您的参观,恭候您的到来。 时间:2024年11月12日至14日 地址: 汉堡会议中心,德国 希施简介 30多年来,CSBio致力为客户提供全方位多肽核酸解决方案。可提供7大类产品: 1)多肽CRDMO...